PMID- 20371665
OWN - NLM
STAT- MEDLINE
DCOM- 20100701
LR  - 20161125
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 95
IP  - 6
DP  - 2010 Jun
TI  - 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 
      123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and 
      hereditary pheochromocytomas and paragangliomas: correlation with vesicular 
      monoamine transporter expression.
PG  - 2800-10
LID - 10.1210/jc.2009-2352 [doi]
AB  - CONTEXT: Pheochromocytomas (PHEOs) and paragangliomas (PGLs) may be better 
      detected by (18)F-fluorodihydroxyphenylalanine-positron emission tomography 
      (FDOPA-PET) than (123)I-metaiodobenzyl-guanidine (123-I-MIBG) scintigraphy. 
      OBJECTIVE: The objective of the study was to correlate functional imaging results 
      with immunohistochemical, molecular-genetic, and biochemical findings. DESIGN AND 
      SETTING: Thirty consecutive patients with suspected PHEO/PGL presenting at a 
      tertiary referral centre were investigated in a prospective study. PATIENTS: 
      Twenty-five patients had confirmed PHEO/PGL. Thirteen of 25 patients had a 
      hereditary PHEO/PGL syndrome (two multiple endocrine neoplasia II, six succinate 
      dehydrogenase complex, subunit D, two succinate dehydrogenase complex, subunit B, 
      one von Hippel Lindau tumor suppressor protein, two Neurofibromatosis-1), and 12 
      of 25 were classified as sporadic. Five patients had hormonally inactive adrenal 
      incidentalomas. MAIN OUTCOME MEASURES: In all patients computed tomography scan 
      and/or magnetic resonance imaging as well as both 123-I-MIBG scintigraphy and 
      FDOPA-PET were performed. Resected tumors were examined by immunohistochemistry 
      for expression of the vesicular monoamine transporter (VMAT)-1 and -2 and other 
      markers. RESULTS: A total of 64 lesions were found with both functional imaging 
      modalities. FDOPA-PET detected 62 lesions, whereas only 34 lesions were detected 
      by 123-I-MIBG scintigraphy. This resulted in an overall sensitivity and 
      specificity for FDOPA-PET of 98 and 100% and for MIBG of 53 and 91%, 
      respectively. Comparable sensitivities were found for adrenal and extraadrenal 
      abdominal lesions (94 vs. 97%), whereas in thoracic/cervical lesions, the 
      sensitivity for 123-I-MIBG scintigraphy (15%) was inferior to that of FDOPA-PET 
      imaging (100%). Immunohistochemistry demonstrated a lack of VMAT-1 expression in 
      all MIBG-negative tumors. Clinical predictors for MIBG negativity were a 
      predominant norepinephrine/normetanephrine secretion, an age less than 45 yr, and 
      a hereditary cause. CONCLUSION: FDOPA-PET is superior to 123-I-MIBG scintigraphy 
      in patients with extraadrenal, predominantly noradrenaline-secreting, and 
      hereditary types of PHEO/PGL. The lack of VMAT-1 expression predicts negativity 
      for MIBG-scintigraphy.
FAU - Fottner, C
AU  - Fottner C
AD  - I. Medical Clinic, Department of Endocrinology and Metabolism, University of 
      Mainz, Langenbeckstrasse 1, 55131 Mainz, Germany. 
      fottner@endokrinologie.klinik.uni-mainz.de
FAU - Helisch, A
AU  - Helisch A
FAU - Anlauf, M
AU  - Anlauf M
FAU - Rossmann, H
AU  - Rossmann H
FAU - Musholt, T J
AU  - Musholt TJ
FAU - Kreft, A
AU  - Kreft A
FAU - Schadmand-Fischer, S
AU  - Schadmand-Fischer S
FAU - Bartenstein, P
AU  - Bartenstein P
FAU - Lackner, K J
AU  - Lackner KJ
FAU - Kloppel, G
AU  - Kloppel G
FAU - Schreckenberger, M
AU  - Schreckenberger M
FAU - Weber, M M
AU  - Weber MM
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20100406
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Biomarkers)
RN  - 0 (Genetic Markers)
RN  - 0 (Radiopharmaceuticals)
RN  - 0 (Vesicular Monoamine Transport Proteins)
RN  - 2C598205QX (fluorodopa F 18)
RN  - 35MRW7B4AD (3-Iodobenzylguanidine)
RN  - 63-84-3 (Dihydroxyphenylalanine)
SB  - IM
MH  - *3-Iodobenzylguanidine
MH  - Adolescent
MH  - Adrenal Gland Neoplasms/*diagnostic imaging/genetics/*metabolism
MH  - Adult
MH  - Aged
MH  - Biomarkers
MH  - Data Interpretation, Statistical
MH  - Dihydroxyphenylalanine/*analogs & derivatives
MH  - Female
MH  - Genetic Markers
MH  - Humans
MH  - Immunohistochemistry
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Paraganglioma/*diagnostic imaging/genetics/*metabolism
MH  - Pheochromocytoma/*diagnostic imaging/genetics/*metabolism
MH  - Positron-Emission Tomography
MH  - *Radiopharmaceuticals
MH  - Tomography, X-Ray Computed
MH  - Vesicular Monoamine Transport Proteins/*biosynthesis/genetics
MH  - Young Adult
EDAT- 2010/04/08 06:00
MHDA- 2010/07/02 06:00
CRDT- 2010/04/08 06:00
PHST- 2010/04/08 06:00 [entrez]
PHST- 2010/04/08 06:00 [pubmed]
PHST- 2010/07/02 06:00 [medline]
AID - jc.2009-2352 [pii]
AID - 10.1210/jc.2009-2352 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2010 Jun;95(6):2800-10. doi: 10.1210/jc.2009-2352. Epub 
      2010 Apr 6.